Stage-specific survival and recurrence in patients with cutaneous malignant melanoma in Europe – a systematic review of the literature

Abstract

BackgroundGiven the increasing incidence in cutaneous malignant melanoma (CMM) and the recent changes in the treatment landscape, it is important to understand stage-specific overall and recurrence-free survival patterns in Europe. Despite publications such as EUROCARE-5, there is limited information on stage-specific survival for CMM in Europe.MethodWe carried out a systematic literature review to provide an up-to-date summary of stage-specific survival and recurrence-free survival patterns in patients with CMM in Europe. Studies were included if they were published in Medline during the past 12 years and included information on stage-specific survival and/or recurrence in CMM.ResultsOf the 8,749 studies identified, 26 studies were included, representing nine countries. Collectively, the studies covered a population of 152,422 patients and included data from 1978 to 2011. Randomized clinical trials and single-center observational studies comprised the most common study designs, including five large registry-based studies. Stage-specific information for survival and recurrence varied: 5-year overall survival: 95%–100% (stage I), 65%–92.8% (stage II), 41%–71% (stage III), and 9%–28% (stage IV); 5-year relapse-free survival was reported less frequently: 56% (stage II), and 28%–44% (stage III). Studies reporting survival by sentinel node (SN) status reported 5-year overall survival as 80%–95% for negative SN (stage I/II) and 35%–75% for positive SN (stage III) status; recurrence-free survival at 5 years: 76%–90% for negative and 35%–58% for positive SN status. Some studies included comparisons of survival by key patient sociodemographic characteristics, suggesting that these have a substantial influence on survival and recurrence estimates.ConclusionThe studies identified in this review show large variations in stage-specific overall and recurrence-free survival by study type and by country. Owing to differing study designs and populations, it is difficult to make detailed comparisons. Large population-based studies that include stage-specific survival and recurrence in Europe are therefore important.

Imaging characteristics of cardiac metastases in patients with malignant melanoma

“…Long-term survival depends on the tumor stage [28], the response to systemic treatment, the surgical resection options and the pre-existing comorbidity of the patient. Due to new therapeutic techniques including tyrosine kinase inhibitors and checkpoint inhibitors, five year survival increased to 37% [29].…”

ECCO essential requirements for quality cancer care for melanoma: Defining how to organise care

“…A recent paper looking at the global picture of melanoma shows that the greatest burden falls on New Zealand, Australia and Europe, and on older people and men (Karimkhani et al, 2017). Information on survival by stage has been limited for skin melanoma; a systematic literature review that included studies from 9 countries in Europe found that the reported 5 year overall survival varies: 95%-100% (stage I), 65%-92.8% (stage II), 41%-71% (stage III), and 9%-28% (stage IV), and concluded that there are large variations in stage-specific overall and recurrence-free survival by study type and by country (Svedman et al, 2016). Despite new treatments, advanced melanoma still has a poor prognosis.…”

Alterations in patient plasma microRNA expression profiles following resection of metastatic melanoma

“…In 2017, an estimated 87 110 patients will be newly diagnosed with melanoma in the United States while 9 730 persons will die of the disease . Surgical resection is the mainstay of therapy . Unfortunately, there are many challenges associated with the management of malignant melanoma.…”